Company news

Guobang Pharma Ltd. Class A (SSE:605507) news

Guobang Pharma Ltd. Class A news releases on 6ix. Latest, Sep 30, 2026: "Guobang Pharma Ltd."Announcement on Obtaining New Veterinary Drug Registration…

Guobang Pharma Ltd. Class A (SSE:605507) news

Press releases & updates

"Guobang Pharma Ltd."Announcement on Obtaining New Veterinary Drug Registration Certificate by Wholly-owned Subsidiary

"Guobang Pharma Ltd."Announcement on a Wholly-owned Subsidiary's Product DMG-PEG2000 Passing the Joint Review and Approval with Its Formulation by the CDE

"Guobang Pharma Ltd."Announcement on Convening the 2026 Semi-annual Performance Briefing

"Guobang Pharma Ltd."Semi-annual Report for 2026

"Guobang Pharma Ltd."Announcement on Progress in Repurchasing Shares

Announcement on the Repurchased Company Shares Reaching 1% and Repurchase Progress

Announcement on Progress in Repurchasing Shares

Announcement on Wholly-owned Subsidiary Participating in Equity Investment Fund

Announcement on Initially Repurchasing the Company's Shares through Auction

Announcement on Shareholding of Top 10 Shareholders and Top 10 Shareholders Without Sales Limit Concerning Shares Repurchase

Announcement on Plan for Repurchasing Shares through Call Auction and Repurchase Report

Announcement on Implementation of Dividend Distribution for 2025

Announcement on Progress in Wholly-owned Subsidiary Participating in the Establishment of Equity Investment Fund

Announcement on the Acquisition of Approval Documents for Veterinary Drug Product Approval Number by the Wholly-owned Subsidiary

Announcement on Resolutions of the 2025 Annual General Meeting

"Corporate Value and Return Enhancement" Action Plan 2026

Announcement on Investment in a New Project by the Company’s Wholly-owned Subsidiary

Announcement on Progress and Implementation Result of Shares Repurchase and Share Changes

Announcement on Listing and Circulation of Partial Restricted Shares in Initial Public Offering

Announcement on the Completion of Non-Trading Transfer and Purchase under the Phase II Employee Stock Ownership Plan

Announcement on Progress in Implementing Phase II Employee Stock Ownership Plans

Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025

Announcement on Convening the Q3 2025 Performance Briefing

Announcement on Completing Term Change of Board of Directors and Appointing Senior Management Members and Securities Affairs Representative

Notice on Convening the 1st Extraordinary General Meeting in 2025

Announcement on Completion of Share Transfer of Ownership by Company Shareholders under Shareholder Agreement

Indicative Announcement on Proposed Share Transfer via Agreement by Company Shareholder to Introduce Strategic Investor and Related Change in Interests

Announcement on Convening the 2025 Semi-annual Performance Briefing

Indicative Announcement on Expiration of the Lock-up Period of Phase I Employee Stock Ownership Plan

2025 Semi-annual Report

Announcement on the Wholly-owned Subsidiary's Participation in the Establishment of the Equity Investment Fund and Completion of the Private Equity Fund Filing

Announcement on Wholly-owned Subsidiary's Product Tulathromycin Passing European Union GMP Certification

Announcement on Progress of Wholly-owned Subsidiary Participating in the Establishment of Equity Investment Fund

Announcement on Implementation of Dividend Distribution for 2024

Announcement on Adjusting Distribution Amount per Share in 2024 Annual Profit Distribution Plan

Announcement on Resolution of the 2024 Annual General Meeting

Announcement on Wholly-owned Subsidiary Participating in the Establishment of Equity Investment Fund

Report for Q1 2025

Announcement on Resolution of the 12th Meeting of the 2nd Board of Directors

Announcement on Receiving the Letter of Commitment for Buyback Loan

Announcement on Shareholding of Top 10 Shareholders and Top 10 Holders of Shares Without Restrictions Concerning Repurchase

Announcement on Repurchasing Shares through Call Auction

Announcement on Wholly-owned Subsidiary Receiving Notice of Approval for Marketing Application of Chemical APIs

Announcement on Completion and Implementation Results of Repurchase

Announcement on Extension of Share Lockup Period by Controlling Shareholder, Actual Controller and Other Shareholders

Announcement on Progress in Repurchasing Shares through Call Auction

Announcement on the Passing of U.S. FDA On-site Inspection of Florfenicol, a Wholly-owned Subsidiary's Product

Announcement on the Progress of Providing Guarantees for Subsidiary

Announcement on the Results of Shareholding Reduction by Shareholders